Antibody-Drug Conjugates (ADCs): Design, Development, and Clinical Impact
Explore antibody-drug conjugates (ADCs) including linker chemistry, payload selection, approved ADCs, toxicity management, and their clinical impact in oncology.
27 articles across four pillars. Filter by category, tag, or full-text search. Fresh drops most Fridays.
Explore antibody-drug conjugates (ADCs) including linker chemistry, payload selection, approved ADCs, toxicity management, and their clinical impact in oncology.
Comprehensive comparison of biologics versus small molecule drugs, covering manufacturing, immunogenicity, cost, administration routes, and clinical trade-offs.
A comprehensive guide to clinical trial phases from Phase 0 through Phase IV, covering sample sizes, endpoints, regulatory requirements, and trial design principles.
Complete guide to the FDA drug approval process covering IND, NDA/BLA applications, accelerated approval, breakthrough therapy designation, and regulatory requirements.
Discover how mRNA technology revolutionized vaccine development, from lipid nanoparticles to modified nucleosides, and its applications beyond COVID-19.
How circular RNAs are made, why they're promising as therapeutics and vaccines, and the delivery and stability advantages driving a wave of clinical programs.
How siRNA and antisense oligonucleotides differ in mechanism, chemistry, delivery, and clinical scope — a practitioner's comparison of the two dominant oligonucleotide modalities.
How endogenous RNAi and engineered siRNA silence gene expression — the Argonaute/RISC machinery, GalNAc delivery, and the growing list of approved siRNA drugs.
A grounded technical explainer on mRNA vaccine architecture — modified nucleosides, lipid nanoparticle delivery, immunogenicity, and where the field is headed after COVID-19.